Embracing failure: What the Phase III progesterone studies can teach about TBI clinical trials

Brain Injury

Volumn 29, Issue 11, 2015, Pages 1259-1272

  Stein, Donald G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; progesterone; ProTECT III; SyNAPSe; traumatic brain injury

Indexed keywords

BIOLOGICAL MARKER; PROGESTERONE; GESTAGEN;

ANIMAL EXPERIMENT; CLINICAL PROTOCOL; DRUG TREATMENT FAILURE; FALSE POSITIVE RESULT; HORMONAL THERAPY; HUMAN; INFORMATION PROCESSING; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUANTITATIVE ANALYSIS; REVIEW; STUDY DESIGN; TRAUMATIC BRAIN INJURY; BRAIN INJURIES; PROCEDURES; TREATMENT FAILURE; TREATMENT OUTCOME;

BRAIN INJURIES; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PROGESTERONE; PROGESTINS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84941874657     PISSN: 02699052     EISSN: 1362301X     Source Type: Journal    
DOI: 10.3109/02699052.2015.1065344     Document Type: Review

References (100)

1. Narayan RK, Michel ME, Ansell B, Baethmann A, Biegon A, Bracken MB, Bullock MR, Choi SC, Clifton GL, Contant CF, et al. Clinical trials in head injury. Journal of Neurotrauma 2002; 19: 503-557.
2. Amiri-Kordestani L, Fojo T. Why do phase iii clinical trials in oncology fail so often? Journal of the National Cancer Institute 2012; 104: 568-569.
3. Lowenstein PR, Castro MG. Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Current Gene Therapy 2009; 9: 368-374.
4. Krum H, Tonkin A. Why do phase III trials of promising heart failure drugs often fail? The contribution of "regression to the truth". Journal of Cardiac Failure 2003; 9: 364-367.
5. Malik RA. Why are there no good treatments for diabetic neuropathy? Lancet Diabetes & Endocrinology 2014; 2: 607-609.
6. Grupke S, Hall J, Dobbs M, Bix GJ, Fraser JF. Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: From review to preview. Clinical Neurology & Neurosurgery 2015; 129C: 1-9.
7. Dyson A, Singer M. Animal models of sepsis: Why does preclinical efficacy fail to translate to the clinical setting? Critical Care Medicine 2009; 37(1 Suppl): S30-37.
8. Jickling GC, Sharp FR. Improving the translation of animal ischemic stroke studies to humans. Metabolic Brain Disease 2015; 30: 461-467.
9. Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature 2012; 483: 531-533.
10. Goodman SN, Gerson J, Mechanistic evidence in evidence-based medicine: A conceptual framework. Rockville, MD: Research White Paper Agency for Healthcare Research and Quality; 2013. Report No.: 13-EHC042-EF.
11. Baulieu EE, Robel P, Schumacher M. Neurosteroids: Beginning of the story. International Review of Neurobiology 2001; 46: 1-32.
12. Schumacher M, Akwa Y, Guennoun R, Robert F, Labombarda F, Desarnaud F, Robel P, De Nicola AF, Baulieu EE. Steroid synthesis and metabolism in the nervous system: Trophic and protective effects. Journal of Neurocytology 2000; 29: 307-326.
13. Lei B, Mace B, Dawson HN, Warner DS, Laskowitz DT, James ML. Anti-inflammatory effects of progesterone in lipopolysaccharide-stimulated bv-2 microglia. PLoS One 2014; 9: e103969.
14. Luoma JI, Kelley BG, Mermelstein PG. Progesterone inhibition of voltage-gated calcium channels is a potential neuroprotective mechanism against excitotoxicity. Steroids 2011; 76: 845-855.
15. Atif F, Sayeed I, Ishrat T, Stein DG. Progesterone with vitamin d affords better neuroprotection against excitotoxicity in cultured cortical neurons than progesterone alone. Molecular Medicine 2009; 15: 328-336.
16. He L, Zhang X, Wei X, Li Y. Progesterone attenuates aquaporin-4 expression in an astrocyte model of ischemia/reperfusion. Neurochemical Research 2014; 39: 2251-2261.
17. Wang X, Zhang J, Yang Y, Dong W, Wang F, Wang L, Li X. Progesterone attenuates cerebral edema in neonatal rats with hypoxic-ischemic brain damage by inhibiting the expression of matrix metalloproteinase-9 and aquaporin-4. Experimental & Therapeutic Medicine 2013; 6: 263-267.
18. Chen G, Shi JX, Qi M, Wang HX, Hang CH. Effects of progesterone on intestinal inflammatory response, mucosa structure alterations, and apoptosis following traumatic brain injury in male rats. Journal of Surgical Research 2008; 147: 92-98.
19. Candolfi M, Jaita G, Zaldivar V, Zarate S, Ferrari L, Pisera D, Castro MG, Seilicovich A. Progesterone antagonizes the permissive action of estradiol on tumor necrosis factor-alpha-induced apoptosis of anterior pituitary cells. Endocrinology 2005; 146: 736-743.
20. Si D, Li J, Liu J, Wang X, Wei Z, Tian Q, Wang H, Liu G. Progesterone protects blood-brain barrier function and improves neurological outcome following traumatic brain injury in rats. Experimental & Therapeutic Medicine 2014; 8: 1010-1014.
21. Pascual JL, Murcy MA, Li S, Gong W, Eisenstadt R, Kumasaka K, Sims C, Smith DH, Browne K, Allen S, et al. Neuroprotective effects of progesterone in traumatic brain injury: Blunted in vivo neutrophil activation at the blood-brain barrier. American Journal of Surgery 2013; 206: 840-845; discussion 845-846.
22. Sayeed I, Stein DG. Progesterone as a neuroprotective factor in traumatic and ischemic brain injury. Progress in Brain Research 2009; 175: 219-237.
23. Deutsch ER, Espinoza TR, Atif F, Woodall E, Kaylor J, Wright DW. Progesterone's role in neuroprotection, a review of the evidence. Brain Research 2013; 1530: 82-105.
24. Garcia-Ovejero D, Gonzalez S, Paniagua-Torija B, Lima A, Molina-Holgado E, De Nicola AF, Labombarda F. Progesterone reduces secondary damage, preserves white matter, and improves locomotor outcome after spinal cord contusion. Journal of Neurotrauma 2014; 31: 857-871.
25. Santarsieri M, Niyonkuru C, McCullough EH, Dobos JA, Dixon CE, Berga SL, Wagner AK. Cerebrospinal fluid cortisol and progesterone profiles and outcomes prognostication after severe traumatic brain injury. Journal of Neurotrauma 2014; 31: 699-712.
26. Yousuf S, Sayeed I, Atif F, Tang H, Wang J, Stein DG. Delayed progesterone treatment reduces brain infarction and improves functional outcomes after ischemic stroke: A time-window study in middle-aged rats. Journal of Cerebral Blood Flow and Metabolism 2014; 34: 297-306.
27. Kipp M, Amor S, Krauth R, Beyer C. Multiple sclerosis: Neuroprotective alliance of estrogen-progesterone and gender. Frontiers in Neuroendocrinology 2012; 33: 1-16.
28. Garay L, Gonzalez Deniselle MC, Sitruk-Ware R, Guennoun R, Schumacher M, De Nicola AF. Efficacy of the selective progesterone receptor agonist nestorone for chronic experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2014; 276: 89-97.
29. Hussain R, El-Etr M, Gaci O, Rakotomamonjy J, Macklin WB, Kumar N, Sitruk-Ware R, Schumacher M, Ghoumari AM. Progesterone and nestorone facilitate axon remyelination: A role for progesterone receptors. Endocrinology 2011; 152: 3820-3831.
30. Kelley BG, Mermelstein PG. Progesterone blocks multiple routes of ion flux. Molecular and Cellular Neurosciences 2011; 48: 137-141.
31. Linnertz R, Wurm A, Pannicke T, Krugel K, Hollborn M, Hartig W, Iandiev I, Wiedemann P, Reichenbach A, Bringmann A. Activation of voltage-gated na(+) and ca(2)(+) channels is required for glutamate release from retinal glial cells implicated in cell volume regulation. Neuroscience 2011; 188: 23-34.
32. Coughlan T, Gibson C, Murphy S. Progesterone, bdnf and neuroprotection in the injured cns. International Journal of Neuroscience 2009; 119: 1718-1740.
33. Frye CA, Koonce CJ, Walf AA. Progesterone, compared to medroxyprogesterone acetate, to c57bl/6, but not 5alpha-reductase mutant, mice enhances object recognition and placement memory and is associated with higher bdnf levels in the hippocampus and cortex. Neurosci Letters 2013; 551: 53-57.
34. Gonzalez SL, Labombarda F, Gonzalez Deniselle MC, Mougel A, Guennoun R, Schumacher M, De Nicola AF. Progesterone neuroprotection in spinal cord trauma involves up-regulation of brain-derived neurotrophic factor in motoneurons. Journal of Steroid Biochemistry & Moleccular Biology 2005; 94: 143-149.
35. Chan M, Chow C, Hamson DK, Lieblich SE, Galea LA. Effects of chronic oestradiol, progesterone and medroxyprogesterone acetate on hippocampal neurogenesis and adrenal mass in adult female rats. Journal of Neuroendocrinology 2014; 26: 386-399.
36. Mouihate A. Tlr4-mediated brain inflammation halts neurogenesis: Impact of hormonal replacement therapy. Frontiers in Cellular Neuroscience 2014; 8: 146. doi: 10.3389/fncel.2014.00146.
37. Barha CK, Ishrat T, Epp JR, Galea LA, Stein DG. Progesterone treatment normalizes the levels of cell proliferation and cell death in the dentate gyrus of the hippocampus after traumatic brain injury. Experimental Neurology 2011; 231: 72-81.
38. Bali N, Arimoto JM, Iwata N, Lin SW, Zhao L, Brinton RD, Morgan TE, Finch CE. Differential responses of progesterone receptor membrane component-1 (pgrmc1) and the classical progesterone receptor (pgr) to 17beta-estradiol and progesterone in hippocampal subregions that support synaptic remodeling and neurogenesis. Endocrinology 2012; 153: 759-769.
39. Li Z, Wang B, Kan Z, Zhang B, Yang Z, Chen J, Wang D, Wei H, Zhang JN, Jiang R. Progesterone increases circulating endothelial progenitor cells and induces neural regeneration after traumatic brain injury in aged rats. Journal of Neurotrauma 2012; 29: 343-353.
40. Anderson GD, Farin FM, Bammler TK, Beyer RP, Swan AA, Wilkerson HW, Kantor ED, Hoane MR. The effect of progesterone dose on gene expression after traumatic brain injury. Journal of Neurotrauma 2011; 28: 1827-1843.
41. Guennoun R, Labombarda F, Gonzalez Deniselle MC, Liere P, De Nicola AF, Schumacher M. Progesterone and allopregnanolone in the central nervous system: Response to injury and implication for neuroprotection. Journal of Steroid Biochemistry & Moleccular Biology 2015; 146: 48-61.
42. Roglio I, Bianchi R, Gotti S, Scurati S, Giatti S, Pesaresi M, Caruso D, Panzica GC, Melcangi RC. Neuroprotective effects of dihydroprogesterone and progesterone in an experimental model of nerve crush injury. Neuroscience 2008; 155: 673-685.
43. OConnor CA, Cernak I, Johnson F, Vink R. Effects of progesterone on neurologic and morphologic outcome following diffuse traumatic brain injury in rats. Experimental Neurology 2007; 205: 145-153.
44. Lee RJ, Kim JK, Chao D, Kuo L, Mally A, McClean ME, Pemberton HE, Wilmington AR, Wong J, Murphy SP. Progesterone and allopregnanolone improves stroke outcome in male mice via distinct mechanisms but neither promotes neurogenesis. Journal of Neurochemistry 2015; 132: 32-37.
45. Yousuf S, Atif F, Sayeed I, Tang H, Stein DG. Progesterone in transient ischemic stroke: A dose-response study. Psychopharmacology 2014; 231: 3313-3323.
46. Chang CM, Su YF, Chang CZ, Chung CL, Tsai YJ, Loh JK, Lin CL. Progesterone attenuates experimental subarachnoid hemorrhage-induced vasospasm by upregulation of endothelial nitric oxide synthase via akt signaling pathway. BioMed Research International 2014; 2014: 207616.
47. Won S, Lee JH, Wali B, Stein DG, Sayeed I. Progesterone attenuates hemorrhagic transformation after delayed tpa treatment in an experimental model of stroke in rats: Involvement of the vegf-mmp pathway. Journal of Cerebral Blood Flow and Metabolism 2014; 34: 72-80.
48. Morales T. Recent findings on neuroprotection against excitotoxicity in the hippocampus of female rats. Journal of Neuroendocrinology 2011; 23: 994-1001.
49. Liu S, Wu H, Xue G, Ma X, Wu J, Qin Y, Hou Y. Metabolic alteration of neuroactive steroids and protective effect of progesterone in alzheimer's disease-like rats. Neural Regeneration Research 2013; 8: 2800-2810.
50. Noorbakhsh F, Baker GB, Power C. Allopregnanolone and neuroinflammation: A focus on multiple sclerosis. Frontiers in Cellular Neuroscience 2014; 8: 134. doi: 10.3389/fncel.2014.00134.
51. Grimm A, Schmitt K, Lang UE, Mensah-Nyagan AG, Eckert A. Improvement of neuronal bioenergetics by neurosteroids: Implications for age-related neurodegenerative disorders. Biochimica et Biophysica Acta 2014; 1842: 2427-2438.
52. Spratt NJ, Tomkins AJ, Pepperall D, McLeod DD, Calford MB. Allopregnanolone and its precursor progesterone do not reduce injury after experimental stroke in hypertensive rats-role of postoperative temperature regulation? PLoS One 2014; 9: e107752.
53. Gilmer LK, Roberts KN, Scheff SW. Efficacy of progesterone following a moderate unilateral cortical contusion injury. Journal of Neurotrauma 2008; 25: 593-602.
54. Wong R, Gibson CL, Kendall DA, Bath PM. Evaluating the translational potential of progesterone treatment following transient cerebral ischaemia in male mice. BMC Neuroscience 2014; 15: 131.
55. Wright DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC, Salomone JP, Dent LL, Harris OA, Ander DS, et al. Protect: A randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine 2007; 49: 391-402.
56. Hannay HJ, Exrachi O, Contant CF, Levin HS. Outcome measures for patients with head injuries: Report of the outcome measure subcommittee. Journal of Head Trauma Rehabilitation 1996: 1141-1150.
57. Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: A randomized controlled trial. Critical Care 2008; 12: R61.
58. Wright DW, Yeatts SD, Silbergleit R, Palesch YY, Hertzberg VS, Frankel M, Goldstein FC, Caveney AF, Howlett-Smith H, Bengelink EM, et al. Very early administration of progesterone for acute traumatic brain injury. New England Journal of Medicine 2014; 371: 2457-2466.
59. Skolnick BE, Maas AI, Narayan RK, van der Hoop RG, MacAllister T, Ward JD, Nelson NR, Stocchetti N, the STI. A clinical trial of progesterone for severe traumatic brain injury. New England Journal of Medicine 2014; 371: 2467-2476.
60. Maas AI, Menon DK, Lingsma HF, Pineda JA, Sandel ME, Manley GT. Re-orientation of clinical research in traumatic brain injury: Report of an international workshop on comparative effectiveness research. Journal of Neurotrauma 2012; 29: 32-46.
61. Menon DK, Maas AI. Traumatic brain injury in 2014: Progress, failures and new approaches for tbi research. Nature Reviews Neurology 2015; 11: 71-72.
62. Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, Eifert B, Long D, Katz DI, Cho S, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. New England Journal of Medicine 2012; 366: 819-826.
63. Zafonte RD, Bagiella E, Ansel BM, Novack TA, Friedewald WT, Hesdorffer DC, Timmons SD, Jallo J, Eisenberg H, Hart T, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline brain injury treatment trial (cobrit). Journal of the American Medical Association 2012; 308: 1993-2000.
64. Rivera SM, Gilman AG. Drug invention and the pharmaceutical industry. In: Brunton LL., editor. Goodman and Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw Hill; 2001. pp 3-16.
65. Goss CW, Hoffman SW, Stein DG. Behavioral effects and anatomic correlates after brain injury: A progesterone dose-response study. Pharmacology, Biochemistry and Behavior 2003; 76: 231-242.
66. Wali B, Ishrat T, Won S, Stein DG, Sayeed I. Progesterone in experimental permanent stroke: A dose-response and therapeutic time-window study. Brain 2014; 137: 486-502.
67. Schwamm LH. Progesterone for traumatic brain injury-resisting the sirens' song. New England Journal of Medicine 2014; 371: 2522-2523.
68. Ioannidis JP. Why most published research findings are false. PLoS Medicine 2005; 2: e124.
69. Mak IW, Evaniew N, Ghert M. Lost in translation: Animal models and clinical trials in cancer treatment. American Journal of Translational Research 2014; 6: 114-118.
70. Gibson CL, Gray LJ, Bath PM, Murphy SP. Progesterone for the treatment of experimental brain injury; a systematic review. Brain 2008; 131: 318-328.
71. Hicks R, Giacino J, Harrison-Felix C, Manley G, Valadka A, Wilde EA. Progress in developing common data elements for traumatic brain injury research: Version two-the end of the beginning. Journal of Neurotrauma 2013; 30: 1852-1861.
72. Bell MJ, Kochanek PM. Pediatric traumatic brain injury in 2012: The year with new guidelines and common data elements. Critical Care Clinics 2013; 29: 223-238.
73. Stead LG, Bodhit AN, Patel PS, Daneshvar Y, Peters KR, Mazzuoccolo A, Kuchibhotla S, Pulvino C, Hatchitt K, Lottenberg L, et al. TBI surveillance using the common data elements for traumatic brain injury: A population study. International Journal of Emergency Medicine 2013; 6: 5. doi: 10.1186/1865-1380-6-5.
74. Green SM. Cheerio, laddie! Bidding farewell to the glasgow coma scale. Annals of Emergency Medicine 2011; 58: 427-430.
75. Retzios AD. Why do so many clinical trials fail? Issues in Clinical Research 2009: 1-46. http://adrclinresearch.com/Issues-in-Clinical-Research-links/Why%20Pivotal%20Clinical%20Trials%20Fail%20-%20Part%201-v12L-a.pdf, accessed 12 May 2015.
76. Lu J, Murray GD, Steyerberg EW, Butcher I, McHugh GS, Lingsma H, Mushkudiani N, Choi S, Maas AI, Marmarou A. Effects of glasgow outcome scale misclassification on traumatic brain injury clinical trials. Journal of Neurotrauma 2008; 25: 641-651.
77. Lu J, Marmarou A, Lapane KL, Investigators I. Impact of gos misclassification on ordinal outcome analysis of traumatic brain injury clinical trials. Journal of Neurotrauma 2012; 29: 719-726.
78. Dunning D, Heath C, Suls J. Flawed self-assessment: Implications for health, education, and the workplace. Psychological Science in the Public Interest 2004; 5: 69-106.
79. McKee AC, Daneshvar DH. The neuropathology of traumatic brain injury. Handbook of Clinical Neurology 2015; 127: 45-66.
80. Katz DI, Cohen SI, Alexander MP. Mild traumatic brain injury. Handbook of Clinical Neurology 2015; 127: 131-156.
81. Pearce AJ, Hoy K, Rogers MA, Corp DT, Maller JJ, Drury HG, Fitzgerald PB. The long-term effects of sports concussion on retired australian football players: A study using transcranial magnetic stimulation. Journal of Neurotrauma 2014; 31: 1139-1145.
82. Covassin T, Schatz P, Swanik CB. Sex differences in neuropsychological function and post-concussion symptoms of concussed collegiate athletes. Neurosurgery. 2007; 61: 345-350; discussion 350-341.
83. Poon W, Vos P, Muresanu D, Vester J, von Wild K, Homberg V, Wang E, Lee TM, Matula C. Cerebrolysin asian pacific trial in acute brain injury and neurorecovery: Design and methods. Journal of Neurotrauma 2015; 32: 571-580.
84. Lingsma HF, Roozenbeek B, Li B, Lu J, Weir J, Butcher I, Marmarou A, Murray GD, Maas AI, Steyerberg EW. Large between-center differences in outcome after moderate and severe traumatic brain injury in the international mission on prognosis and clinical trial design in traumatic brain injury (IMPACT) study. Neurosurgery 2011; 68: 601-607; discussion 607-608.
85. Roozenbeek B, Lingsma HF, Maas AI. New considerations in the design of clinical trials for traumatic brain injury. Clinical Investigations (London) 2012; 2: 153-162.
86. Price M, Hertzberg V, Wright DW. Does the sliding dichotomy result in higher powered clinical trials for stroke and traumatic brain injury research? Clinical Trials 2013; 10: 924-934.
87. Nichol AD, Higgins AM, Gabbe BJ, Murray LJ, Cooper DJ, Cameron PA. Measuring functional and quality of life outcomes following major head injury: Common scales and checklists. Injury 2011; 42: 281-287.
88. Shukla D, Devi BI, Agrawal A. Outcome measures for traumatic brain injury. Clinical Neurology & Neurosurgery 2011; 113: 435-441.
89. Bagiella E, Novack TA, Ansel B, Diaz-Arrastia R, Dikmen S, Hart T, Temkin N. Measuring outcome in traumatic brain injury treatment trials: Recommendations from the traumatic brain injury clinical trials network. Journal of Head Trauma Rehabilitation 2010; 25: 375-382.
90. Alali AS, Vavrek D, Barber J, Dikmen S, Nathens AB, Temkin NR. Comparative study of outcome measures and analysis methods for traumatic brain injury trials. Journal of Neurotrauma 2015; 32: 581-589.
91. Norris J. $17m DoD award aims to improve clinical trials for traumatic brain injury. San Francisco: University of California San Francisco; 2014. Available online at: http://www.ucsf.edu/news/2014/10/118596/us-aims-traumatic-brain-injury-clinical-trial-success, accessed 2 February 2014.
92. Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT, Workshop Scientific T, Advisory Panel M. Classification of traumatic brain injury for targeted therapies. Journal of Neurotrauma 2008; 25: 719-738.
93. Meythaler JM, Brunner RC, Johnson A, Novack TA. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: A pilot double-blind randomized trial. Journal of Head Trauma Rehabilitation 2002; 17: 300-313.
94. Bhandari M, Giannoudis PV. Assessing patient outcomes: Pearls for clinical practice and research. Injury 2011; 42: 231.
95. Hong CM, Tosun C, Kurland DB, Gerzanich V, Schreibman D, Simard JM. Biomarkers as outcome predictors in subarachnoid hemorrhage-a systematic review. Biomarkers 2014; 19: 95-108.
96. Geschwind N. Problems in the anatomical understanding of the aphasias. In: Stein D, Rosen J, Butters N., editors. Plasticity and recovery of function in the central nervous system. New York: Academic Press; 1974. pp 467-508.
97. Luria AR. Higher cortical functions in man. New York: Basic Books; 1966.
98. Goldberg SI, Niemierko A, Turchin A. Analysis of data errors in clinical research databases 2008. MIA Annual Symposium Proceedings 2008; 2008: 242-246.
99. Yin G. Clinical trial design: Bayesian and frequentist adaptive methods. Hoboken, NJ: Wiley; 2012.
100. He W, Pinero J, Kuznetsova OM, editors. Practical considerations for adpative trial design and implementation. Statistics for biology and health. New York: Springer; 2014